Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 15/20 | 0.84 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.84 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.84 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.84 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.84 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.84 |
| ▸ | STK10 | O94804 | 1/20 | 0.84 |
| ▸ | INSR | P06213 | 1/20 | 0.84 |
| ▸ | RET | P07949 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | SRC | P12931 | 1/20 | 0.84 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.84 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.84 |
| ▸ | CDK2 | P24941 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15766039 | 0.97 | HDAC3 (0.82) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL15766109 | 0.96 | EGFR (0.86) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL15766062 | 0.95 | EGFR (0.81) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL15766012 | 0.94 | EGFR (0.82) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL18691854 | 0.93 | EGFR (0.97) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL2505835 | 0.93 | EGFR (0.97) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL14982050 | 0.93 | EGFR (0.92) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| SCHEMBL15766037 | 0.93 | ABCB11 (0.87) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL3233815 | 0.92 | EGFR (0.96) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL2501563 | 0.92 | EGFR (0.96) | EGFRERBB2ABCB11MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740729-B1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RES (CN) | 2020-11-25 | — | — | EP | claimed |
| US-9499530-B2 | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RESEARCH (CN) | 2016-11-22 | — | — | US | claimed |
| US-20150080392-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG PHARMACEUTICAL CO. LTD (CN) | 2015-03-19 | — | — | US | claimed |
| EP-2740729-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | Hangzhou Minsheng Institutes for Pharma Research (CN) | 2014-06-11 | — | — | EP | claimed |
| EP-2740729-B1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RES (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-9499530-B2 | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RESEARCH (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20150080392-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG PHARMACEUTICAL CO. LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| EP-2740729-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | Hangzhou Minsheng Institutes for Pharma Research (CN) | 2014-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080392-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | LCK, ZAP70, FYN | EGFR 24/4885ABL1 5/4885PDGFRB 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.